Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1624 1642 1643 1644 1646 1671
This examiner grants 69% of resolved cases
Karl J. Puttlitz is an examiner in Tech Center 1600 and Art Unit 1621. He has managed 1432 resolved cases with an allowance rate of 69.1 percent. This 69.1 percent rate indicates that a majority of applications in his docket reach a grant, providing a baseline for applicant expectations.
The interview lift is 18.6 percent. This figure suggests that conducting an interview is a productive strategy for increasing the likelihood of a grant. The 18.6 percent lift provides a meaningful boost to the allowance rate, making it a recommended tactic for practitioners to use during prosecution.
The median days to allowance is 932. This timeline represents the typical duration for applications to reach a final grant. With 1432 resolved cases, these metrics offer a clear view of the examiner's performance. The 932-day median defines the expected prosecution experience for applicants in this docket.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19682032 | COMPOSITIONS FOR TARGETING MUSCLE CELLS AND USES THEREOF | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18593665 | ION EXCHANGE MEMBRANE CHROMATOGRAPHY | Non-Final OA | Genentech, Inc. |
| 19407141 | LIGAND-DRUG CONJUGATES | Final Rejection | Tripartite Therapeutics Inc. |
| 18695618 | PYRROLOBENZODIAZEPINE CONJUGATES FOR CANCER TREATMENT | Non-Final OA | SONY GROUP CORPORATION |
| 18552478 | ENHANCING T CELL FUNCTION THROUGH THE USE OF PROXIMAL SIGNALING MOLECULES | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18029798 | GENE CORRECTION FOR X-CGD IN HEMATOPOIETIC STEM AND PROGENITOR CELLS | Non-Final OA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 17611758 | Metabolite Delivery for Modulating Metabolic Pathways of Cells | Final Rejection | Arizona Board of Regents on Behalf of Arizona State University |
| 18440760 | STABLE PERCARBOXYLIC ACID COMPOSITIONS AND USES THEREOF | Non-Final OA | ECOLAB USA INC. |
| 19255499 | TREATMENT OF HR+/HER2- BREAST CANCER USING SACITUZUMAB GOVITECAN | Final Rejection | Gilead Sciences, Inc. |
| 18260273 | METHODS FOR ENHANCEMENT OF ENGINEERED CELL THERAPIES IN CANCER TREATMENT | Non-Final OA | PURDUE RESEARCH FOUNDATION |
| 18692514 | CHIMERIC SECRETORY COMPONENT POLYPEPTIDES AND USES THEREOF | Non-Final OA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS |
| 17627613 | METHOD OF TREATING NEOPLASTIC DISEASES WITH A CDC42-SPECIFIC INHIBITOR | Final Rejection | Children's Hospital Medical Center |
| 18252818 | PHARMACEUTICAL FORMULATION | Final Rejection | AstraZeneca UK Limited |
| 18175265 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | Non-Final OA | Bayer Pharma Aktiengesellschaft |
| 17927225 | LIQUID FORMULATION OF LONG-ACTING CONJUGATE OF GLP-2 | Final Rejection | HANMI PHARM. CO., LTD. |
| 18410200 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Non-Final OA | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. |
| 18408826 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Non-Final OA | GENEQUANTUM HEALTHCARE (SUZHOU) CO., LTD. |
| 18427510 | COMBINATION THERAPIES USING AN ANTI-BCMA ANTIBODY DRUG CONJUGATE (ADC) IN COMBINATION WITH A GAMMA SECRETASE INHIBITOR (GSI) | Non-Final OA | CELGENE CORPORATION |
| 18258343 | Therapeutic RNA for Treating Cancer | Final Rejection | BioNTech SE |
| 18001374 | TREATMENT OF DISEASES CHARACTERIZED BY OVEREXPRESSION OF ERYTHROPOIETIN-PRODUCING HEPATOCELLULAR RECEPTOR A2 (EPHA2) | Final Rejection | BicycleTx Limited |
| 18427293 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES AND USES THEREOF | Non-Final OA | MEDIMMUNE LIMITED |
| 17793005 | ANTI-TROP-2 ANTIBODY-EXATECAN ANALOG CONJUGATE AND MEDICAL USE THEREOF | Final Rejection | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. |
| 18222313 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | Non-Final OA | Seagen Inc. |
| 17634026 | TREATMENT OF CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | Non-Final OA | SEAGEN INC. |
| 18012710 | CONJUGATE OF SAPONIN AND SINGLE-DOMAIN ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING SAID CONJUGATE, THERAPEUTIC USE THEREOF | Final Rejection | SAPREME TECHNOLOGIES B.V. |
| 18087678 | METHODS FOR THE PREPARATION OF LINKER PAYLOAD CONSTRUCTS | Final Rejection | SYNAFFIX B.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy